Alimera Sciences, Inc. (ALIM)

Market Cap	35.54M
Revenue (ttm)	52.61M
Net Income (ttm)	-17.36M
Shares Out	7.00M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	65.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,025
Open	5.15
Previous Close	5.27
Day's Range	5.15 - 5.25
52-Week Range	3.94 - 7.92
Beta	1.32
Analysts	Buy
Price Target	12.92 (+154.3%)
Earnings Date	Oct 26, 2022

About ALIM

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies,...

• Industry: Pharmaceuticals
• IPO Date: Apr 22, 2010
• CEO: Richard Eiswirth
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: ALIM

Full Company Profile

Financial Performance

In 2021, ALIM's revenue was $59.03 million, an increase of 16.15% compared to the previous year's $50.82 million. Losses were -$4.37 million, -18.11% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ALIM stock is "Buy." The 12-month stock price forecast is 12.92, which is an increase of 154.33% from the latest price.

Price Target

$12.92

(154.33% upside)

Analyst Consensus: Buy

Stock Forecasts